Last edition
News about Global Pharma
AstraZeneca Reports 11 Percent Revenue Growth, Commits to USD 50 Bn US Expansion
For H1 2025, AstraZeneca’s total revenue rose 11 percent at constant exchange rates (CER) to USD 28.0 billion, driven by double-digit growth in both its oncology and biopharmaceuticals divisions.
Global Pharma | 29/07/2025 | By Dineshwori | 350
Merck, BMS, Pfizer to Be Hit Hard by Looming Patent Cliff: Report Warns
Major pharmaceutical players, including Merck, Bristol Myers Squibb (BMS), Johnson and Johnson, Pfizer, and Novartis, are expected to experience significant revenue losses as several of their blockbuster drugs approach patent expirations, according to a new report by Research and Markets.
Global Pharma | 28/07/2025 | By Dineshwori | 1186
Hengrui Pharma has signed agreements with GSK to develop up to 12 innovative medicines across respiratory, immunology and inflammation, and oncology. It includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD and additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK.
Global Pharma | 28/07/2025 | By Mrinmoy Dey | 425
Elpis Biopharmaceuticals has signed an MoU with the National Cancer Centre Singapore. The collaboration focuses on advancing clinically validated armoured CAR technologies into first-in-human trials in Singapore and accelerating translational research from bench-to-bedside.
Global Pharma | 28/07/2025 | By Mrinmoy Dey | 334
AstraZeneca's Imfinzi Granted Priority Review by FDA for Early-Stage Gastric and GEJ Cancers
The US Food and Drug Administration (FDA) has accepted AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) and granted Priority Review for the treatment of patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
Global Pharma | 28/07/2025 | By Dineshwori | 222
Pfizer and BioNTech's Updated COVID-19 Vaccine Secures EMA Nod, Awaits Final EU Approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Pfizer- BioNTech's LP.8.1-adapted monovalent COVID-19 vaccine in the European Union.
Global Pharma | 28/07/2025 | By Dineshwori | 291
Matchpoint, Novartis Partner to Develop Oral Inhibitors for Multiple Inflammatory Diseases
Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis to develop and commercialise oral covalent inhibitors for multiple inflammatory diseases.
Global Pharma | 28/07/2025 | By Dineshwori | 225
India's Pharma Exports Surge 92 Percent in Six Years: Anupriya Patel
Driven by various government schemes, India’s drug and pharmaceutical exports have risen from INR 1,28,028 crore in FY2018-19 to INR 2,45,962 crore in FY2024-25.
Global Pharma | 26/07/2025 | By Dineshwori | 387
India-UK FTA: A New Era for India's Pharma Industry
India currently exports pharmaceutical goods worth approximately USD 914 million (around INR 7,600 crore) annually to the UK. With the new FTA in place, this figure is expected to surge significantly, particularly for generic medicines, bulk drugs, and biosimilars.
Global Pharma | 26/07/2025 | By Darshana | 284
Laurus Labs Posts Strong Q1 FY26 Results With 31 Percent Revenue Growth
Laurus Labs has reported strong financial results for the first quarter of FY26, with consolidated revenues reaching INR 1,570 crore—a 31 percent year-on-year increase.
Global Pharma | 26/07/2025 | By Dineshwori | 1821
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy